Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2014 now is available at the company’s website: www.medivir.com.
- 2014 was an important year for Medivir. We created value in the company through our sales successes with OLYSIO® (simeprevir), and hence revenues, both from sales and from royalties. The most important events in 2014 were, without doubt, the global market launch of OLYSIO® and the approval of OLYSIO® as a pharmaceutical for the treatment of chronic HCV in Europe, enabling us to launch it in the Nordic region. We are proud of the fact that our work is helping to cure seriously ill people and save lives and of the fact that Medivir has established itself as one of the Nordic region’s leading research based pharmaceutical companies”, said Medivir’s CEO, Niklas Prager, in his CEO’s Statement in this year’s Annual Report.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.